



AMENDMENTS TO THE CLAIMS

This listing of the claims will replace all prior versions, and listings, of claims in the application:

1-35. (Cancelled)

36. (Currently amended) A pharmaceutical composition comprising a combination of a selective or specific COX 2 inhibitor or a pharmaceutically acceptable salt or derivative thereof, an opiate or a pharmaceutically acceptable salt or derivative thereof, and a centrally-acting cyclo-oxygenase inhibitor or a pharmaceutically acceptable salt or derivative thereof, as active ingredients, and a pharmaceutically acceptable carrier, ~~wherein at least one of the active ingredients is provided in a sub-therapeutic amount.~~

37. (Currently amended) The A pharmaceutical composition according to claim 36, wherein the selective or specific COX 2 inhibitor is selected from the group consisting of meloxicam, celecoxib, rofecoxib and pharmaceutically acceptable salts or derivatives thereof.

38. (Currently amended) The A pharmaceutical composition according to claim 36, wherein the opiate is selected from the group consisting of codeine, morphine, tramadol, fentanyl and pharmaceutically acceptable salts or derivatives thereof.

39. (Currently amended) The A pharmaceutical composition according to claim 36, wherein the centrally-acting cyclo-oxygenase inhibitor is paracetamol.

40. (Currently amended) The A pharmaceutical composition according to claim 36, wherein the selective or specific COX 2 inhibitor, opiate and centrally-acting cyclo-oxygenase inhibitor are provided in amounts such that the combination is therapeutically effective in treating pain, in an algesic and/or hyperalgesic state, with or without fever.

41. (Currently amended) The A pharmaceutical composition according to claim 36, comprising a combination of meloxicam, or a pharmaceutically acceptable salt or derivative thereof, codeine, or a pharmaceutically acceptable salt or derivative thereof, and paracetamol.

42. (Currently amended) The A pharmaceutical composition according to claim 36, wherein the composition comprises a combination of meloxicam, or a pharmaceutically acceptable salt or derivative thereof, tramadol, or a pharmaceutically acceptable salt or derivative thereof, and paracetamol.

43. (Currently amended) The A pharmaceutical composition according to claim 36, consisting essentially of meloxicam, codeine and paracetamol.

44. (Currently amended) The A pharmaceutical composition according to claim 36, wherein all of the active ingredients are provided in sub-therapeutic amounts.

45. (Currently amended) A combination of a selective or specific COX 2 inhibitor, an opiate and a centrally-acting cyclo-oxygenase inhibitor, or pharmaceutically acceptable derivatives or salts thereof, as active ingredients, for use in the treatment of pain, in an algesic and/or hyperalgesic state, with or without fever, ~~wherein at least one of the active ingredients is provided in a sub-therapeutic amount~~, the amounts of the active ingredients being selected such that the combination is therapeutically effective.

46. (Previously presented) The combination of claim 45, wherein the selective or specific COX 2 inhibitor is selected from the group consisting of meloxicam, celecoxib, rofecoxib and pharmaceutically acceptable salts or derivatives thereof.

47. (Previously presented) The combination of claim 45, wherein all of the active ingredients are provided in sub-therapeutic amounts.

48. (Previously presented) The combination of claim 45, wherein the pain is associated with inflammation.

49. (Previously presented) The combination according to claim 48, wherein the pain is associated with trauma, osteoarthritis, rheumatoid arthritis, non-inflammatory myalgia or dysmenorrhoea.

50-54. (Cancelled)

55. (Currently amended) A method of treating pain, in an algesic and/or hyperalgesic state, with or without fever, comprising administering to a patient in need thereof a therapeutically effective amount of a combination of a selective or specific COX 2 inhibitor, an opiate and a centrally-acting cyclo-oxygenase inhibitor, or pharmaceutically acceptable salts or derivatives thereof, as active ingredients, ~~wherein at least one of the active ingredients is provided in a sub-therapeutic amount.~~

56. (Currently amended) The A method according to claim 55, wherein the selective or specific COX 2 inhibitor is selected from the group consisting of meloxicam, celecoxib, rofecoxib and pharmaceutically acceptable salts or derivatives thereof.

57. (Currently amended) The A method according to claim 55, wherein the opiate is selected from the group comprising codeine, morphine, tramadol, fentanyl and pharmaceutically acceptable salts or derivatives thereof.

58. (Currently amended) The A method according to claim 55, wherein the centrally-acting cyclo-oxygenase inhibitor is paracetamol.

59. (Currently amended) The A method according to claim 55, comprising administering to a patient in need thereof a combination of meloxicam, codeine and paracetamol.

60. (Currently amended) The A method according to claim 55, comprising administering to a patient in need thereof a combination of meloxicam, tramadol and paracetamol.

61. (Currently amended) The A method according to claim 59, wherein the meloxicam is provided in an amount to give a daily dose from about 0.5 mg to about 30 mg.

62. (Currently amended) The A method according to claim 59, wherein the daily dose of meloxicam is from about 7.5 mg to about 15 mg.

63. (Currently amended) The A method according to claim 59, wherein the codeine is provided in an amount to give a daily dose from about 10 mg to about 360 mg.

64. (Currently amended) The A method according to claim 60, wherein the tramadol is provided in an amount to give a daily dose from about 25 mg to about 500mg.

65. (Currently amended) The A method according to claim 55, wherein the paracetamol is provided in an amount to give a daily dose from about 60 mg to about 4000 mg.

66. (Currently amended) The A method according to claim 59, wherein the ratio of meloxicam to codeine is about 0.05 to 2.0 meloxicam: 1 to 6 codeine.

67. (Currently amended) The A method according to claim 66, wherein the ratio of meloxicam to codeine is from about 0.1 to 1.0 meloxicam: 2 to 4 codeine.

68. (Previously presented) The combination of claim 45, wherein the opiate is selected from the group consisting of codeine, morphine, tramadol, fentanyl and pharmaceutically acceptable salts or derivatives thereof.

69. (Previously presented) The combination of claim 45, wherein the centrally-acting cyclo-oxygenase inhibitor is paracetamol.

70. (Previously presented) The combination of claim 45, wherein the selective or specific COX 2 inhibitor, opiate and centrally-acting cyclo-oxygenase inhibitor are provided in amounts such that the combination is therapeutically effective in treating pain, in an analgesic and/or hyperalgesic state, with or without fever.

71. (Previously presented) The combination of claim 45, wherein the combination comprises meloxicam, or a pharmaceutically acceptable salt or derivative thereof, codeine, or a pharmaceutically acceptable salt or derivative thereof, and paracetamol.
72. (Previously presented) The combination of claim 45, wherein the combination comprises meloxicam, or a pharmaceutically acceptable salt or derivative thereof, tramadol, or a pharmaceutically acceptable salt or derivative thereof, and paracetamol.
73. (Previously presented) The combination of claim 45, wherein the combination consists essentially of meloxicam, codeine and paracetamol
74. (Previously presented) The combination of claim 45, wherein all of the active ingredients are provided in sub-therapeutic amounts
75. (Currently amended) The A method according to claim 60, wherein the meloxicam is provided in an amount to give a daily dose from about 0.5 mg to about 30 mg.
76. (Currently amended) The A method according to claim 60, wherein the daily dose of meloxicam is from about 7.5 mg to about 15 mg.
77. (New) The pharmaceutical composition according to claim 36, wherein at least one of the active ingredients is provided in a subtherapeutic amount.
78. (New) The combination according to claim 45, wherein at least one of the active ingredients is provided in a subtherapeutic amount.
79. (New) The method according to claim 55 wherein at least one of the active ingredients is provided in a subtherapeutic amount.